Heart Valve Repair Co. NeoChord Closes $25M Series D

Heart Valve Repair Co. NeoChord Closes $25M Series D

The St. Louis Park-based company’s products treat mitral valve regurgitation, a common heart malfunction experienced by Americans.

Privately-held heart device maker NeoChord Inc. announced Monday the closing of a $25 million funding round—its largest to date—that received contributions from several out-of-state investors.

The St. Louis Park-based company, founded in 2007, develops products for surgical use to treat patients suffering from mitral valve regurgitation. Much like it sounds, the condition involves the heart’s mitral valve not closing properly, causing blood to backflow in the heart. The condition is one of the most frequent indications for valve surgery and one that many Americans experience. More than 200,000 mitral valve regurgitation cases are reported annually, according to Mayo Clinic.

NeoChord’s flagship mitral valve repair product, the NeoChord Artificial Chordae Delivery System, has been on the market in Europe since 2012. In the meantime, the company has been developing two additional mitral valve repair systems to add to its portfolio, both of which will be aided by the company’s Series D funding round.

“We are pleased to close the Series D financing to resource the acceleration of the on-going development of our transcatheter edge-to-edge and chordal repair programs,” said NeoChord president and CEO David Chung in a statement. “As the leader in chordal repair, we will continue our strong commercial presence internationally, while fast-tracking the development of our catheter-based programs.”

NeoChord’s Series D round was led by U.S. Venture Partners, a health care- and technology-focused venture capital firm out of California. New York-based firm Deerfield Management co-led the round, while Baird Capital, a VC firm from Chicago, continued its support, NeoChord said.

“NeoChord has established strong, clinical credibility with its current platform and has entrenched beating heart chordal repair as an important treatment option for the mitral toolbox,” said Casey Tansey of U.S. Venture Partners. “We are confident in the team’s ability to leverage their robust commercial experience in chordal repair with the current device while driving the development of their two transcatheter repair programs.”

In tandem with U.S. Venture Partners’ investment, NeoChord is also inducting Tansey into its board of directors.